Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_assertion evidence source_evidence_literature NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_assertion SIO_000772 23847380 NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_assertion wasDerivedFrom befree-20150227 NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_assertion wasGeneratedBy ECO_0000203 NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
- befree-20150227 importedOn "2015-02-27" NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.